《Nature,3月25日,Cancer drug trials on hold amid coronavirus disruption》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-03-26
  • When 2020 began, Neena Nizar and her family were poised to harvest the fruit of a decade of hard work and sacrifice: a clinical trial of an experimental treatment for her two sons’ rare genetic disorder that was slated to start before the year’s end.

    “I can’t even put into words what we’ve been able to do to get to this point,” she says. “My kids have given bone biopsies; I gave up my job and moved to a new country. We’ve just been going, going, going.”

  • 原文来源:https://www.nature.com/articles/d41586-020-00889-6
相关报告
  • 《Nature,2月25日,Trends in COVID-19 therapeutic clinical trials》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-03-01
    • The COVID-19 pandemic has stimulated intense efforts to find effective therapeutics for all stages of the disease. Unfortunately, the scope, scientific rigour and clinical value of research activities undertaken worldwide have been difficult to gauge, especially amid the rapidly evolving landscape. From the very beginning of the search for effective preventive and therapeutic agents, the US Food and Drug Administration (FDA) has been committed to helping to identify and develop evidence-based therapeutics through well-designed clinical trials. It is critically important to protect patients from inefficacious or unsafe drugs while advancing those evidence-based efforts efficiently — without duplication or otherwise wasting resources — to bring effective interventions to patients. To inform such efforts, the FDA has sought a comprehensive understanding of the global COVID-19 clinical trials landscape. Here, we present our assessment of ongoing COVID-19 therapeutic clinical development efforts worldwide.
  • 《Nature,3月17日,Coronavirus latest: First vaccine clinical trials begin in United States》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-18
    • 17 March 00:30 GMT — First vaccine clinical trials begin in the United States The first phase I clinical trial for a potential COVID-19 vaccine has begun in Seattle, Washington. Four adults, the first of 45 eventual participants, received their first doses of an experimental vaccine developed through a partnership between the US National Institute of Allergy and Infectious Diseases (NIAID) and Moderna, a biotechnology company based in Cambridge, Massachusetts. But although it is an important milestone, the phase I trial is just the beginning of a long process to test the drug’s safety and efficacy.